

SIRONA BIOCHEM CORP.
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited – Prepared by Management)
(Expressed in Canadian Dollars)
FOR THE NINE MONTHS ENDED JULY 31, 2017

**NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS**

Under National Instrument 51-102, Part 4, subsection 4.3(3), if an auditor has not performed a review of the condensed interim consolidated financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim consolidated financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these condensed interim consolidated financial statements in accordance with the standards established by the Canadian Institute of Chartered Accountants for a review of condensed interim consolidated financial statements by an entity's auditor.

SIRONA BIOCHEM CORP.
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(Expressed in Canadian dollars)

As at	July 31, 2017	October 31, 2016
ASSETS		
Current Assets		
Cash and cash equivalents	\$ 86,356	\$ 613,158
Trade receivables	21,270	30,612
Tax receivables (Note 6)	548,992	261,661
Share subscription receivable	-	114,250
Prepaid expenses and deposits (Note 7)	102,894	112,289
	759,512	1,131,970
Property and equipment (Note 8)	241,816	278,078
Intangible assets (Note 9)	1,592,719	1,566,991
Goodwill (Note 10)	148,280	148,008
	\$ 2,742,327	\$ 3,125,047
LIABILITIES		
Current Liabilities		
Trade and other payables (Note 11)	\$ 530,021	\$ 454,313
Current portion of lease obligation (Note 13)	34,080	33,789
Deferred revenue (Note 14)	54,500	54,500
	618,601	542,602
Long-term debt (Note 12)	1,994,198	725,911
Lease obligation (Note 13)	183,784	208,932
Employee benefits (Note 15)	87,101	84,428
	\$ 2,883,684	\$ 1,561,873
SHAREHOLDERS' EQUITY		
Share capital (Note 16)	\$ 19,149,087	\$ 18,998,847
Contributed surplus	3,624,803	3,627,302
Foreign translation reserve	52,151	13,515
Accumulated deficit	(22,967,398)	(21,076,490)
	(141,357)	1,563,174
	\$ 2,742,327	\$ 3,125,047

APPROVED ON BEHALF OF THE BOARD:

"Howard Verrico" Director
Howard Verrico

"Casper Bych" Director
Casper Bych

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

SIRONA BIOCHEM CORP.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE LOSS
(Expressed in Canadian Dollars)

	Three Months Ended July 31, 2017	Three Months Ended July 31, 2016	Nine Months Ended July 31, 2017	Nine Months Ended July 31, 2016
Revenue	\$ 2,274	\$ 2,801	\$ 3,416	\$ 398,988
Expenses				
Research expenses	269,734	330,573	737,723	1,004,407
Consulting fees	63,166	120,973	145,137	338,941
Office and administration	47,798	91,430	159,759	247,926
Accounting and audit fees	42,211	48,398	228,278	203,549
Wages, salaries and benefits	68,376	72,517	254,580	173,261
Management fees	36,000	96,000	108,000	169,500
Travel and entertainment	7,926	37,600	23,279	79,029
Rental expenses	15,932	-	47,819	-
Investor relations	15,240	15,540	51,358	45,160
Legal fees	10,171	3,645	22,031	21,036
Filing fees and transfer agent fees	5,520	6,693	24,822	21,391
Management conferences and meetings	-	11,295	9,050	18,623
Withholding tax	-	39,150	-	39,150
Exchange gain/loss	1,976	5,249	(2,271)	5,362
Share-based payments	19,328	33,894	27,741	99,089
	(601,104)	(910,156)	(1,833,890)	(2,067,436)
Other income/(expenses)				
Other income (expenses)	7,408	2,608	19,095	3,369
Finance income	5,856	241	5,876	633
Finance expense	(36,744)	(13,459)	(81,989)	(38,886)
	(23,480)	(10,610)	(57,018)	(34,884)
Loss for the period	(624,584)	(920,766)	(1,890,908)	(2,102,320)
Income taxes recovery	-	1,779	-	21,029
Net loss for the period	(624,584)	(918,987)	(1,890,908)	(2,081,291)
Other comprehensive loss for the period				
Foreign currency translation	38,636	15,623	48,075	(1,990)
Net loss and comprehensive loss for the period	\$ (585,948)	\$ (903,364)	\$ (1,842,833)	\$ (2,083,281)
Loss per share - basic and diluted	\$ (0.00)	\$ (0.00)	\$ (0.01)	\$ (0.01)
Weighted average number of common shares				
outstanding - basic and diluted	165,197,548	161,994,586	165,176,885	157,917,362

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

SIRONA BIOCHEM CORP.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS PERIOD ENDED JULY 31,
(Expressed in Canadian Dollars)

	2017	2016
Operating Activities		
Net loss for the period	\$ (1,890,908)	\$ (2,081,291)
Items not requiring use of cash:		
Amortization of equipment and intangible assets	121,524	148,990
Interest accretion	-	37,763
Share-based payments	27,741	62,325
Changes in operating assets and liabilities:		
Trade and other receivable	(279,207)	229,449
Prepaid expenses	23,686	270,373
Accounts payable and accrued liabilities	165,528	(53,513)
Employee benefit	2,339	14,184
Rental security deposit	106	-
Deferred revenue	(88,551)	(20,217)
Deferred tax asset (liability)	-	(21,029)
Unrealized exchange gain/loss	37,058	(10,573)
Cash (used in) operating activities	(1,880,684)	(1,423,539)
Investing Activities		
Purchase of equipment	-	(277,416)
Acquisition of intangible assets	(106,907)	(116,991)
Cash (used in) investing activities	(106,907)	(394,407)
Financing Activities		
Option and warrants exercised	234,250	212,570
Borrowings/(repayment)	1,227,552	247,979
Shares issued for cash, net of issuance cost	-	755,500
Cash provided by financing activities	1,461,802	1,216,049
Increase (decrease) in cash and cash equivalents	(525,789)	(601,897)
Effect of exchange rate fluctuations	(1,013)	(972)
Cash and cash equivalents, beginning of period	613,158	1,543,105
Cash and cash equivalents, end of period	\$ 86,356	\$ 940,236

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

SIRONA BIOCHEM CORP.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDER'S EQUITY
(Expressed in Canadian Dollars, except share numbers)

	Issued Common Shares		Shares to be issued	Contributed surplus	Foreign translation reserve	Equity portion of convertible debenture	Accumulated Deficit	Total Equity
	Number	Amount						
BALANCE, OCTOBER 31, 2015	151,402,715	\$ 16,692,255	\$ -	\$ 3,527,327	\$ 22,686	\$ 5,717	\$(18,101,723)	\$ 2,146,262
Loss for the period	-	-	-	-	-	-	(2,081,291)	(2,081,291)
Exercise of options	1,109,000	244,724	-	(93,154)	-	-	-	151,570
Fair value of options issued	-	-	-	99,089	-	-	-	99,089
Exercise of warrants	380,000	96,606	-	(20,606)	-	-	-	76,000
Loan conversion	5,583,333	670,000	-	-	-	-	-	670,000
Issuance of shares, net of share issuance cost	4,147,500	698,725	106,775	-	-	-	-	805,500
Currency translation	-	-	-	-	(1,990)	-	-	(1,990)
BALANCE, JULY 31, 2016	162,622,548	\$ 18,402,310	\$ 106,775	\$ 3,512,656	\$ 20,696	\$ 5,717	\$(20,183,014)	\$ 1,865,140
BALANCE, OCTOBER 31, 2016	165,097,548	\$ 18,998,847	-	\$ 3,627,302	\$ 13,515	\$ -	\$(21,076,490)	\$ 1,563,174
Loss for the period	-	-	-	-	-	-	(1,890,908)	(1,890,908)
Issuance of stock options (Note 16)	-	-	-	27,741	-	-	-	27,741
Exercise of options (Note 16)	700,000	150,240	-	(30,240)	-	-	-	120,000
Foreign currency translation	-	-	-	-	38,636	-	-	38,636
BALANCE, JULY 31, 2017	165,797,548	\$ 19,149,087	\$ -	\$ 3,624,803	\$ 52,151	\$ -	\$(22,967,398)	\$ (141,357)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2017
(Expressed in Canadian Dollars)

1. NATURE OF OPERATIONS AND GOING CONCERN

The Company was incorporated on October 19, 2006 under the Business Corporations Act of British Columbia. The Company is a development stage public company listed for trading on the TSX Venture Exchange (the “Exchange”) under the symbol SBM. On May 1, 2009 the Company completed its qualifying transaction by entering into a Licensing Agreement with TFChem S.A.R.L. (“TFC”), a biopharmaceutical company based in Rouen, France, and changed its name from High Rider Capital Inc. to Sirona Biochem Corp. On March 31, 2011, the Company completed its business acquisition of TFC (See note 8). The Company is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety.

The head office, principal address and registered and records office of the Company are located at 605 – 889 West Pender Street, Vancouver, BC, V6C 3B2.

These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards applicable to a going concern, which assumes that the Company will be able to meet its obligations and continue its operations for its next fiscal year. Realization values may be substantially different from carrying values in these unaudited condensed interim consolidated financial statements which do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern. As at July 31, 2017, the Company had working capital of \$140,911 (October 31, 2016 - \$589,368); had an accumulated deficit of \$22,967,398 (October 31, 2016 - \$21,076,490); and expects to incur further losses in the development of its business, all of which cast doubt about the Company’s ability to continue as a going concern. Management believes that its existing cash resources, together with funds obtained from share issuances, are adequate for the total amount of planned research program. The Company’s ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations.

2. BASIS OF PRESENTATION

The unaudited condensed interim consolidated financial statements (the “Interim Financial Statements”) include the accounts of the Company and its wholly owned subsidiary, TFChem S.A.R.L. Any reference to “the Company” throughout these Interim Financial Statements refers to the Company and its subsidiary. All inter-entity transactions have been eliminated. The results of the operations of the subsidiary acquired during the year are included from the date of acquisition.

The Interim Financial Statements are presented in Canadian dollars and all values are rounded to the nearest thousand except when otherwise indicated.

The Interim Financial Statements have been prepared in accordance with International Accounting Standard (“IAS”) 34, Interim Financial Reporting, as issued by the International Accounting Standards Board (“IASB”), using the accounting policies the Company adopted in its consolidated financial statements as at and for the financial year ended October 31, 2016.

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2017
(Expressed in Canadian Dollars)

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

The accounting policies set out below have been applied consistently to all periods presented in the consolidated financial statements.

Principles of consolidation

These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, TFChem S.A.R.L. (“TFC”), a biopharmaceutical company based in Rouen, France.

Subsidiaries are entities controlled by the Company. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of a subsidiary are included in the consolidated financial statements from the date that control commences until the date that control ceases.

All significant inter-company balances and transactions between the Company and its wholly-owned subsidiary have been eliminated in preparing the consolidated financial statements.

Foreign currency

Foreign currency transactions

Transactions in foreign currencies are translated to the respective functional currencies of the Company and its subsidiary at the exchange rate in effect at the transaction date. Monetary assets and liabilities denominated in other than the functional currency are translated at the exchange rates in effect at the financial position date. The resulting exchange gains and losses are recognized in profit or loss. Non-monetary assets and liabilities denominated in other than the functional currency that are measured at fair value are translated to the functional currency at the exchange rate at the date that the fair value is determined. None-monetary items that are measured in terms of historical cost in other than the functional currency are translated using the exchange rate at the date of transaction.

Foreign operations

For consolidation purposes, the assets and liabilities of foreign operations are translated to the presentation currency using the exchange rate prevailing at the financial position date. The income and expenses of foreign operations are translated to the presentation currency using the average rates of exchange during the year. All resulting exchange differences are recorded as other comprehensive income (loss) and accumulated in a separate component of shareholders’ equity, described as foreign translation reserve.

Financial instruments

Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. Financial liabilities are derecognized when obligations are discharged, cancelled or expired. Financial assets and liabilities are offset and the net amount reported in the statement of financial position when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or realize the asset and settle the liability simultaneously.

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2017
(Expressed in Canadian Dollars)

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Financial instruments (continued)

Classification and measurement

At initial recognition, financial instruments are classified into the following categories depending on the purposes for which the instruments were acquired:

- Financial assets and liabilities at fair value through profit and loss (“FVTPL”):
A financial asset or liability is classified as FVTPL if acquired principally for the purpose of selling or repurchasing in the short-term. Derivatives are also included in this category unless they are designated as hedges. Financial instruments in this category are recognized initially and subsequently at fair value. Gains and losses arising from changes in fair value are presented in the statement of comprehensive income (loss) in the period in which they arise. Financial assets and liabilities at FVTPL are classified as current except for the portion expected to be realized or paid beyond twelve months of the financial position date, which is classified as non-current.
- Available-for-sale:
Financial assets classified as available-for-sale are measured at fair value with unrealized gains and losses recognized in other comprehensive income (loss) except for losses in value that are considered other than temporary or a significant or prolonged decline in the fair value of that investment below its cost in which case the loss is recognized in the statement of comprehensive income (loss). They are included in current assets to the extent they are expected to be realized within 12 months after the end of the reporting period.
- Loans and receivables:
Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Loans and receivables are initially recognized at the amount expected to be received less, when material, a discount to reduce the loans and receivables to fair value. Subsequently, loans and receivables are measured at amortized cost using the effective interest method less a provision for impairment. They are included in current assets to the extent they are expected to be realized within 12 months after the end of the reporting period.
- Held-to-maturity investments
Held-to-maturity investments are non-derivative financial assets with fixed or determinable payments and fixed maturities that the Company’s management has the positive intention and ability to hold to maturity. These assets are measured at amortized cost using the effective interest method less a provision for impairment. They are included in non-current assets, except for those which are expected to mature within 12 months after the end of the reporting period.
- Financial liabilities at amortized cost:
Financial liabilities other than those classified as FVTPL are initially recognized at the amount required to be paid less, when material, a discount to reduce the payables to fair value. Subsequently, they are measured at amortized cost using the effective interest method. Financial liabilities at amortized costs are classified as current liabilities if payment is due within twelve months after the end of the reporting period. Otherwise, they are presented as non-current liabilities.

Transaction costs associated with financial assets or financial liabilities carried at FVTPL are expensed as incurred while transaction costs associated with all other financial assets or financial liabilities are included in the initial carrying amount of the asset or liabilities.

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2017
(Expressed in Canadian Dollars)

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Financial instruments (continued)

Classification and measurement (continued)

The Company classifies cash and cash equivalents as FVTPL, trade and other receivables and share subscription receivable as loans and receivables, and trade and other payable, convertible debentures, lease obligation, and long term debt as financial liabilities at amortized cost. The Company does not have any derivative financial instruments.

Impairment of financial assets

Financial assets not carried at FVTPL are assessed for impairment at each reporting date by determining whether there is objective evidence that indicates that a loss event has occurred after the initial recognition of the asset, and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably.

Impairment losses on available-for-sale financial assets are recognized by transferring the cumulative loss that has been recognized in other comprehensive income (loss) and presented in accumulated other comprehensive income (loss) in equity, to net income (loss). The cumulative loss that is removed from other comprehensive income (loss) and recognized in net income (loss) is the difference between the acquisition costs, net of any principal repayment and amortization, and the current fair value less any impairment loss previously recognized in net (income) loss. If subsequently the fair value of any impaired available-for sale financial assets increases, then the impairment loss is reversed with the amount of the reversal recognized in net income (loss).

Cash and cash equivalents

Cash and cash equivalents consist of cash and highly liquid instruments that are readily convertible to cash with a maturity of three months or less when initially purchased.

Trade and other receivables

Trade and other receivables are stated at their amortized cost less impairment losses. An allowance for doubtful account is established when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of the receivables.

Property and equipment

Property and equipment are stated at cost less accumulated depreciation and any accumulated impairment losses. The cost of property and equipment includes the acquisition cost and any direct costs to bring the asset into productive use at its intended location. Depreciation is calculated on a straight-line basis over the estimated useful lives. One-half of the depreciation amounts are taken in the year of acquisition. Depreciation methods and useful lives are reviewed at each reporting date and adjusted if appropriate. The estimated useful lives as follows:

Industrial equipment	1 to 4 years
Computer equipment	1 to 3 years
Office equipment	3 years
Furniture	3 to 5 years
Scientific instrument under finance lease	the shorter of estimated useful lives or lease term

Property and equipment are written down to the net recoverable value when management determines there has been a change in circumstances which indicates its carrying amount may not be recoverable. Any gain or loss on disposal of an item of equipment is recognized in profit or loss within the period of disposal.

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2017
(Expressed in Canadian Dollars)

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Leases

Finance leases

Leases of property and equipment where substantially all the risks and benefits incidental to the ownership of the asset are transferred the Company are classified as finance leases. Assets under finance leases are capitalized by recording an asset and a liability at the lower of the fair value of the leased property and equipment or the present value of the minimum lease payments, including any guaranteed residual values. Minimum lease payments are apportioned between the reduction of the outstanding lease liability and finance expense. Finance expense is allocated to each period during the lease term so as to produce a constant periodic rate of interest on the remaining balance of liability. Leased assets are depreciated on a straight-line basis over the shorter of their estimated useful lives or the lease term, unless there is a reasonable certainty the Company will obtain ownership of the leased asset by the end of the lease term in which case it is depreciated over its useful life.

Operating leases

Other leases are operating leases and not recognized in the statement of financial position. Lease payments made under operating leases are charged as expenses on a straight-line basis over the term of the lease. Lease incentives received under operating leases are recognized as a reduction to the lease expense on a straight-line basis over the life of the lease term.

Intangible assets

Intangible assets acquired through a business combination are identified and recognized separately from goodwill where they arise from legal or contractual rights or are capable of being separated from the acquiree and sold, transferred, licensed or exchanged. The cost of such intangible assets is deemed to be their fair value at the acquisition date. Intangible assets not acquired through a business combination are reported at cost less accumulated amortization and accumulated impairment losses.

Internally-generated intangible assets are recognized to the extent the criteria in IAS 38 - Intangible Assets are met. Development costs for internally-generated intangible assets are capitalized at cost if, and only if, the Company can demonstrate:

- the technical feasibility of completing the asset so that it will be available for use or sale;
- the intention to complete the intangible asset and use or sell it;
- the ability to use or sell the intangible asset;
- how the intangible asset will generate probable future economic benefits;
- the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and
- the ability to measure reliably the expenditure attributable to the intangible asset during its development.

Subsequent to initial recognition, they are recorded at cost less accumulated amortisation and accumulated impairment losses. Identified intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives. The estimated lives are reviewed at least annually and are adjusted as appropriate. The estimated useful lives for the current and comparative years are as follows:

Acquired technology platform	20 years
Patents	20 ~25 years
Software	12 months

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2017
(Expressed in Canadian Dollars)

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Goodwill

Under the acquisition method of accounting the costs of business combinations are allocated to the assets acquired and liabilities assumed based on the estimated fair value at the date of acquisition. The excess of the fair value of consideration paid over the fair value of the identifiable net assets acquired is recorded as goodwill. Goodwill is not amortized but tested for impairment annually or more frequently if changes in circumstances indicate a potential impairment. After initial recognition, goodwill is measured at cost less any accumulated impairment losses.

For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Company's cash-generating units ("CGU"), or a group of CGUs, that are expected to benefit from the synergies the business combination. A CGU is defined as the smallest identifiable group of assets that generate cash inflows, which are largely independent of the cash inflows from other assets. A group of CGUs represents the lowest level within the entity at which the goodwill is monitored for internal management purposes, which is not higher than an operating segment.

On disposal of the relevant CGU, the attributable amount of goodwill is included in the determination of the profit or loss on disposal.

Impairment of non-financial assets

The carrying amounts of the Company's non-financial assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated. For goodwill and intangible assets that have indefinite useful lives, the recoverable amount is estimated annually.

The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. Fair value less costs to sell is defined as the estimated price that would be received on the sale of the asset in an orderly transaction between market participants at the measure date. For the purposes of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other groups of assets. Cash-generating units to which goodwill have been allocated reflects the lowest level at which goodwill is monitored for internal reporting purposes.

An impairment loss is recognized if the carrying amount of an asset or its cash-generating unit exceeds its estimated recoverable amount. Impairment losses are recognized in profit or loss. Impairment losses recognized in respect of the cash generating units are allocated first to reduce the carrying amount of any goodwill allocated to the units, and then to reduce the carrying amounts of the other assets in the unit on a pro-rata basis.

An impairment loss in respect of goodwill is not reversed. In respect of other assets, impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined net of depreciation or amortization, if no impairment loss had been recognized. A reversal of an impairment loss is recognized immediately in profit or loss.

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2017
(Expressed in Canadian Dollars)

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Provisions

Provisions for legal or constructive obligations are recognized when the Company has a present legal or constructive obligation that has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risk specific to the obligation. The increase in the provision due to passage of time is recognized as interest expense.

Share capital

The Company's ordinary common shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares, warrants and stock options, net of any tax effects, are recognized as a deduction from equity.

Revenue recognition

The Company from time to time enters into licensing and collaboration agreements. The terms of the agreements may include non-refundable signing and licensing fees, milestone payments and royalties on any product sales derived from licensing arrangements. License fees are recognized as revenue when persuasive evidence of an arrangement exists, the fee is fixed or determinable, delivery or performance has substantially completed and collection is reasonably assured. If there are no substantive performance obligations over the life of the contract, the upfront non-refundable payment is recognized when the underlying performance obligation is satisfied. If substantive performance obligations are satisfied over time or over the life of the contract, payments received are deferred and recognized over the period when the performance obligations are fulfilled. The term over which upfront fees are recognized is revised if the period over which the Company maintains substantive performance obligations changes. Milestone payments are immediately recognized as licensing revenue when the condition is met, if the milestone is not a condition to future deliverables and collectability is reasonably assured. Otherwise, they are recognized over the remaining term of the agreement or the performance period. Deferred revenue represent cash received from customers in excess of revenue recognized on uncompleted contracts.

Research and development

Expenditures on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in profit or loss as incurred. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. No development expenditures have been deferred to date.

Research and development costs includes fees paid to contract research organizations and other vendors who conduct certain research and development activities on behalf of the Company. The amount of expenses recognized in a period related to research arrangements with third parties is based on estimates of work performed using an accrual basis of accounting. These estimates are based on services provided, contractual terms and experience with similar contracts. The Company monitors these factors and adjusted the estimates accordingly.

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2017
(Expressed in Canadian Dollars)

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Employee benefit

Short-term employee benefits

Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognized for the amount expected to be paid under short-term cash bonus if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and the obligation can be estimated reliably.

Long term employee benefits

A liability is recognized for benefits accruing to employees when it is probable that settlement will be required and it is capable of being measured reliably. Liabilities recognized in respect of employee benefits which are not due to be settled within one year are measured at the present value of the estimated future cash outflows to be made by the Company in respect of services provided by employees up to the reporting date. As of July 31, 2017 and October 31, 2016, the employee benefit amount represent the retirement allowance payable accrued by TFC.

Share-based payment transactions

The Company awards shares of the Company's stock or stock options to directors, officers, employees and/or 3rd party goods/service providers and uses the fair-value based method of accounting for share-based compensations for all awards granted. The resulting compensation expense, based on the fair value of the awards granted is charged to profit or loss over the period that the employees unconditionally become entitled to the award or when goods/services are rendered, with a corresponding increase to contributed surplus. Any consideration received on exercise of stock options or purchase of shares, together with the amount initially recorded in contributed surplus, is credited to share capital.

The Board of Directors grants stock options with vesting periods determined at the sole discretion of the Board and at prices reflecting the share price on the date the options were granted. An individual is classified as an employee when the individual is an employee for legal or tax purposes ("direct employee") or provides services similar to those performed by a direct employee, including directors of the Company.

The fair value of employee stock options granted is measured using the Black-Scholes option pricing model as of the grant date, taking into account the terms and conditions upon which the options are granted. The cumulative expense recognized at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Company's best estimate of the number of options that will ultimately vest. The compensation expense for a period represents the movement in cumulative expense recognized as at the beginning and end of that period.

Where the terms of a stock option are modified, the minimum expense recognized is the expense as if the terms had not been modified. An additional expense is recognized for any modification which increases the total fair value of the stock-based compensation arrangement, or is otherwise beneficial to the employee as measured at the date of modification over the remaining vesting period.

Share-based payments to non-employees are measured at the fair value of the goods or services received or the fair value of the equity instruments issued, if it is determined the fair value of the goods or services cannot be reliably measured, and are recorded at the date the goods or services are received.

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2017
(Expressed in Canadian Dollars)

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Government assistance and research & development tax credits

Government assistance and research and development tax credits are recorded as either a reduction of the cost of the applicable assets, or credited against the related expense incurred in profit or loss, as determined by the terms and conditions of the agreements under which the assistance is provided to the Company or the nature of the expenditures which give rise to the credits.

Government assistance are recorded at their fair value where there is a reasonable assurance that the grants will be received and the Company will comply with all attached conditions. Research and development tax credits are accrued when qualifying expenditures are made and there is reasonable assurance that the credits will be realized.

Income Taxes

The Company follows the asset and liability method of accounting for income tax. Income tax expense comprises current and deferred tax. Income tax expense is recognized in the statement of comprehensive income (loss) except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity.

Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years.

Deferred tax is recognized on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized on the initial recognition of assets or liabilities in a transaction that is not a business combination, nor is it recognized for taxable temporary differences arising on the initial recognition of goodwill. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously. A deferred tax asset is recognized to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

Related Party Transactions

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control, related parties may be individuals or corporate entities. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

Other comprehensive income (loss)

Other comprehensive income (loss) is the change in the Company's net assets that results from transactions, events and circumstances from sources other than the Company's shareholders and includes items that would not normally be included in net income (loss) such as unrealized gains or losses on available-for-sale investments and translation gains or losses on translation of foreign operations to the presentation currency of the Company.

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2017
(Expressed in Canadian Dollars)

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Segment reporting

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment.

Earnings (loss) per share

Basic earnings (loss) per share is computed by dividing the profit (loss) for the year attributable to ordinary common shareholders of the Company by the weighted average number of common shares outstanding during the year, adjusted for treasury shares. Diluted earnings (loss) per share is calculated using the treasury stock method.

Under the treasury stock method the dilution is computed based upon the number of common shares issued should “in the money” options or warrants, if any, be exercised. When the effects of outstandingly stock-based compensation arrangements would be anti-dilutive, diluted loss per share is not calculated. As at July 31, 2017 and October 31, 2016, stock options and warrants were not included in the computation of loss per share as they are out of the money and such inclusion would be anti-dilutive.

4. CRITICAL JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

Critical accounting judgments

The critical judgments that the Company’s management has made in the process of applying the Company’s accounting policies that have the most significant effect on the amounts recognized in these consolidated financial statements are as follows:

Evaluation of the Company’s ability to continue as a going concern

Management has applied judgements in the assessment of the Company's ability to continue as a going concern when preparing these consolidated financial statements. Management prepares the consolidated financial statements on a going concern basis unless management either intends to liquidate the entity or to cease trading, or has no realistic alternative but to do so. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but is not limited to, twelve months from the end of the reporting period. The assessment of the Company’s ability to execute its strategy and finance the operations through achieving positive cash flow from operations or by obtaining additional funding through debt or equity financing involves judgments. Management monitors future cash requirements to assess the Company’s ability to realize assets and discharge its liabilities in the normal course of operations.

Determination of functional currency of the Company

The functional currency for each of the Company and its subsidiary is the currency of the primary economic environment in which each entity operates. The determination of each entity’s functional currency requires analyzing facts that are considered primary factors, and if the result is not conclusive, the secondary factors. The analysis requires the management to apply significant judgment since primary and secondary factors may be mixed. In determining its functional currency, the management analyzed both the primary and secondary factors, including the currency of each entity’s operating cash flow, and sources of financing.

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2017
(Expressed in Canadian Dollars)

**4. CRITICAL JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY
(continued)**

Critical accounting judgments (continued)

Capitalization of development costs

Management applies judgement in evaluating whether or not development costs incurred by the Company in the internal development of intangible assets meet the criteria for capitalizing. Management determined that as at July 31, 2017 and October 31, 2016, it was not able to demonstrate with sufficient certainty that it is probable the economic benefits will flow to the Company. Accordingly, all internal development costs incurred to date have been expensed.

Key sources of estimation uncertainty

Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of the financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions made, relate to, but are not limited to, the following:

Impairment of non-financial assets

Determining the amount of asset impairment requires an estimation of the recoverable amount, which is defined as the higher of fair value less the cost of disposal or value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risk specific to the asset. In assessing fair value less costs to sell, the price that would be received on the sale of an asset in an orderly transaction between market participants at the measurement date is estimated. Many of factors used in assessing recoverable amounts are outside of the control of management and it is reasonably likely that assumptions and estimates will change from period to period. These changes may result in future impairments in the Company's long term assets such as plant and equipment or investment in joint venture. For example, the revenue growth rate could be lower than projected due to economic, industry or competitive factors, or the discount rate used in the value in use model could increase due to a change in market interest rates. In addition, future goodwill impairment charges may be necessary if the market capitalization decreased due to a decline in the trading price of the Company's common stock, which could negatively impact the fair value of the Company's non-financial assets.

Convertible debentures

The calculation of the fair value of the debt component of the convertible debenture requires using an interest rate that the Company would have had to pay had the loan been obtained without a conversion feature. Such interest rate requires management's estimate by reference to loan interest paid by comparable companies in the similar sector. The Company estimates 14% being the reasonable interest rate a comparable company in technology sector would likely pay in obtaining loans. Changes to these estimates may affect the carrying value of convertible debentures and the equity portion of convertible debentures.

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2017
(Expressed in Canadian Dollars)

4. CRITICAL JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY
(continued)

Key sources of estimation uncertainty (continued)

Long-term employee benefits

The present value of long-term employee benefits is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that have terms to maturity approximating the terms of the related employee benefits. Determination of the benefit costs requires assumptions such as the discount rate to measure employee benefits obligations, the projected age of employees upon retirement, the probability of survival, the probability of employee turnover, and the amount of the employees' last month salary prior to retirement. Actual results may differ from results which are estimated based on assumptions.

Depreciation and amortization

Property and equipment are depreciated based on the estimated useful life less their estimated residual value. Intangible assets are amortized based on estimated useful life less their estimated residual value. Significant assumptions are involved in the determination of useful life and residual values and no assurance can be given that actual useful lives and residual values will not differ significantly from current assumptions. Actual useful life and residual values may vary depending on a number of factors including internal technical evaluation, physical condition of the assets and experience with similar assets. Changes to these estimates may affect the carrying value of equipment, net income (loss) and comprehensive income (loss) in future periods.

Share-based payments

The Company uses the fair value method of valuing compensation expense associated with the Company's share-based compensation plan. Estimating fair value requires determining the most appropriate valuation model for a grant of equity instruments, which is dependent on the terms and conditions of the grant. Option-pricing models require the use of highly subjective estimates and assumptions including the expected stock price volatility and expected life of options. Changes in the underlying assumptions can materially affect the fair value estimates and, therefore, existing models do not necessarily provide reliable measurement of the fair value of the Company's stock options.

Current and deferred taxes

Accounting for income taxes is a complex process requiring management to interpret frequently changing laws and regulations and make judgments relating to the application of tax law, the estimated timing of temporary difference reversals, and the estimated realization of tax assets. The Company recognizes the deferred tax benefit related to deferred tax assets to the extent recovery is probable. Assessing the recoverability of deferred tax assets requires management to make significant estimates of future taxable profit. In addition, future changes in tax laws could limit the ability of the Company to obtain tax deductions in the future periods. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred tax assets recorded at the reporting date could be impacted. In addition, all tax filings are subject to subsequent government audits and potential reassessment. These interpretations, judgments and changes related to them impact current and deferred tax provisions, deferred tax assets and liabilities and results of operations.

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
 July 31, 2017
 (Expressed in Canadian Dollars)

5. IFRS STANDARDS ISSUED BUT NOT YET EFFECTIVE

The following is an overview of accounting standard changes that the Company will be required to adopt in future years. The Company is still in the process of assessing the impact on the financial statements of these new standards:

IFRS 9 Financial instruments

On July 24, 2014, the IASB issued the complete IFRS 9, Financial Instruments (“IFRS 9”). IFRS 9 introduces new requirements for the classification and measurements of financial assets. Under IFRS 9, financial assets are classified and measured based on the business model in which they are held and the characteristics of their contractual cash flows. The standard introduces additional changes relating to financial liabilities and amends the impairment model by introducing a new “expected credit loss” model for calculating impairment. It also includes a new general hedge accounting standard which aligns hedge accounting ore closely with risk management. IFRS 9 is effective for reporting periods beginning on or after January 1, 2018 and must be applied retrospectively with some exemptions. Early adoption is permitted.

IFRS 15 Revenue from contracts with customers

On May 28, 2014 the IASB issued IFRS 15, Revenue from Contracts with Customers (“IFRS 15”). IFRS 15 deals with revenue recognition and establishes principles for reporting useful information to users of financial statements about the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. Revenue is recognized when a customer obtains control of a good or service and thus has the ability to direct the use and obtain the benefits from the goods or services. The standard replaces IAS 18 Revenue and IAS 11 Construction contracts and related interpretations. IFRS15 is effective for reporting periods beginning on or after January 1, 2018 with early application permitted.

IFRS 16 Leases

On January 13, 2016, the International Accounting Standards Board published a new standard, IFRS 16, Leases, eliminating the current dual accounting model for lessees, which distinguishes between on-balance sheet finance leases and off-balance sheet operating leases. Under the new standard, a lease becomes an on-balance sheet liability that attracts interest, together with a new right-of-use asset. In addition, lessees will recognize a front-loaded pattern of expense for most leases, even when cash rentals are constant. IFRS 16 is effective for reporting periods beginning on or after January 1, 2019, with early application permitted.

Other new standards or amendments are either not applicable or not expected to have a significant impact on the Company’s consolidated financial statements.

6. TAX RECEIVABLES

Tax receivables as detailed below:

	July 31, 2017	October 31, 2016
R&D tax credit, VAT, and other tax receivables	\$ 542,178	\$ 193,341
GST/HST receivables	6,814	61,345
	\$ 548,992	\$ 276,034

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2017
(Expressed in Canadian Dollars)

7. PREPAID EXPENSES AND DEPOSITS

	July 31, 2017	October 31, 2016
Prepaid expenses	\$ 93,068	\$ 102,357
Rental deposits	9,826	9,932
	<u>\$ 102,894</u>	<u>\$ 112,289</u>

8. PROPERTY, PLANT AND EQUIPMENT

Cost	Industrial Equipment	Computer Equipment	Office Equipment	Scientific instrument under finance lease	Furniture	Total
November 1, 2015	\$ 113,502	\$ 49,120	\$ 6,754	\$ -	\$ 14,390	\$ 183,766
Additions	6,570	17,657	-	257,495	1,236	282,958
Disposals	-	(39,974)	-	-	-	(39,974)
Exchange difference	1,927	824	-	(385)	243	2,609
October 31, 2016	\$ 121,999	\$ 27,627	\$ 6,754	\$ 257,110	\$ 15,869	\$ 429,359
Exchange difference	220	(2,653)	(6,754)	473	29	(8,685)
July 31, 2017	\$ 122,219	\$ 24,974	\$ -	\$ 257,583	\$ 15,898	\$ 420,674

Accumulated Amortization	Industrial Equipment	Computer Equipment	Office Equipment	Scientific instrument under finance lease	Furniture	Total
November 1, 2015	\$ 101,230	\$ 36,121	\$ 6,754	\$ -	\$ 10,483	\$ 154,588
Additions	10,029	6,167	-	14,816	1,109	32,121
Disposals	-	(37,911)	-	-	-	(37,911)
Exchange difference	1,711	617	-	(23)	178	2,483
October 31, 2016	\$ 112,970	\$ 4,994	\$ 6,754	\$ 14,793	\$ 11,770	\$ 151,281
Additions	3,671	4,536	-	26,984	849	36,040
Exchange difference	285	(2,599)	(6,754)	566	39	(8,463)
July 31, 2017	\$ 116,926	\$ 6,931	\$ -	\$ 42,343	\$ 12,658	\$ 178,858

Net book value	Industrial Equipment	Computer Equipment	Office Equipment	Scientific instrument under finance lease	Furniture	Total
October 31, 2016	\$ 9,029	\$ 22,633	\$ -	\$ 242,317	\$ 4,099	\$ 278,078
July 31, 2017	\$ 5,293	\$ 18,043	\$ -	\$ 215,240	\$ 3,240	\$ 241,816

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2017
(Expressed in Canadian Dollars)

9. INTANGIBLE ASSETS

Cost	Acquired intangible assets	Patents	Software	Total
November 1, 2015	\$ 1,626,751	\$ 333,931	\$ -	\$ 1,960,682
Additions	-	102,434	8,135	110,569
Exchange difference	27,702	5,533	(12)	33,223
October 31, 2016	\$ 1,654,453	\$ 441,898	\$ 8,123	\$ 2,104,474
Additions	-	107,049	-	107,049
Exchange difference	3,040	3,938	15	6,993
July 31, 2017	\$ 1,657,493	\$ 552,885	\$ 8,138	\$ 2,218,516

Accumulated Amortization	Acquired intangible assets	Patents	Software	Total
November 1, 2015	\$ 386,962	\$ 22,221	\$ -	\$ 409,183
Additions	82,678	27,970	5,775	116,423
Exchange difference	6,466	5,419	(8)	11,877
October 31, 2016	\$ 476,106	\$ 55,610	\$ 5,767	\$ 537,483
Additions	60,807	24,750	1,966	87,523
Exchange difference	190	546	55	791
July 31, 2017	\$ 537,103	\$ 80,906	\$ 7,788	\$ 625,797

Net book value	Acquired intangible assets	Patents	Software	Total
October 31, 2016	\$ 1,178,347	\$ 386,288	\$ 2,356	\$ 1,566,991
July 31, 2017	\$ 1,120,390	\$ 471,979	\$ 350	\$ 1,592,719

Acquired technology platform consist of intellectual properties and a proprietary carbohydrate chemistry platform utilized for developing and identifying lead compounds that were recognized from the business acquisition of TFC in 2011. As at July 31, 2017 and October 31, 2016, no impairment was recognized for intangible assets.

10. GOODWILL

Goodwill was recognized as a result of the acquisition of TFC in 2011. As at October 31, 2016 and 2015, the Company assessed the impairment of goodwill. The Company and its subsidiary, TFC, operates in one operating segment, which constitutes a single cash-generating unit. The recoverable amount of the CGU was determined based on a value in use calculation using a discounted cash flow model with cash flow projections over a five-year period.

The calculation of value in use are most sensitive to the following key assumptions: 1) cash inflows from milestone payments and future royalty payments based on estimated probability of success of its various phases of clinical trials; 2) cash outflow relating to estimated operating costs based on historical expenses; 3) discount rate based on the weighted average cost of capital (“WACC”); and 4) terminal value assumptions. The Company’s value in use test was based on a WACC ranging from 31.2% to 45.8%; estimated probability of success of various phases of clinical trials ranging from 16.8% to 100.0%; and a terminal year earnings before interest, taxes, depreciation and amortization utilized by a terminal value of multiplier ranging from 2.28 to 3.43. Based on the result of the value in use test, the Company has determined that the recoverable amount of the CGU exceeded its carrying amount.

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2017
(Expressed in Canadian Dollars)

11. TRADE AND OTHER PAYABLES

	July 31, 2017	October 31, 2016
Trade payables	\$ 246,492	\$ 189,254
Interest payable	21,325	21,325
Accrued liabilities	119,929	117,126
Payroll liabilities	142,275	126,608
	<u>\$ 530,021</u>	<u>\$ 391,136</u>

12. LONG-TERM DEBT

	July 31, 2017	October 31, 2016
BPI loan ⁽¹⁾	\$ 741,838	\$ 725,911
Convertible debentures ⁽²⁾	1,252,360	1,397,079
Total long-term debt	<u>\$ 1,994,198</u>	<u>\$ 1,397,079</u>

⁽¹⁾ During the year ended October 31, 2015, TFC entered into two loan agreements with Bpifrance Financement (“BPI”) for a total amount of \$1,213,464 (€840,000). The loans were provided to TFC as a regional innovation fund to assist with TFC’s research project and the loans are non-interest bearing with fixed repayment terms commencing September 30, 2018, if the research project is successful. In addition to the repayment, commencing April 1, 2018, an amount equal to 23.42% of the revenue generated in the previous year by the research project has to be repaid to BPI annually until the loan have been repaid in full. On November 31, 2014, the Company received the first change of the loan totalling \$750,758 (€504,000).

⁽²⁾ On February 3, 2017, the Company has closed a non-brokered private placement of convertible notes (“Note”) for gross proceeds of \$665,360. Each Note will be convertible at the option of the holder into one common share of the Company at a conversion price of \$0.18 per share during the 18 month term of the Notes. The Notes will mature in 18 months from the date of issuance and bear interest at the rate of 12% per annum, payable quarterly, until the Notes are converted or repaid. The Company will be entitled to repay the principal amount of the Notes, together with accrued and unpaid interest, at any time commencing four months after the date of issuance.

On June 5, 2017, the Company has closed a non-brokered private placement of convertible notes (“Note”) for gross proceeds of \$587,000. Each Note will be convertible at the option of the holder into one common share of the Company at a conversion price of \$0.18 per share during the 18 month term of the Notes. The Notes will mature in 18 months from the date of issuance and bear interest at the rate of 12% per annum, payable quarterly, until the Notes are converted or repaid. The Company will be entitled to repay the principal amount of the Notes, together with accrued and unpaid interest, at any time commencing four months after the date of issuance.

13. LEASE OBLIGATION

On June 6, 2016, TFC entered into a lease agreement with NATIXIS Lease to lease a scientific instrument. The lease agreement bears interests of 2.7% annually, and expires in seven years on May 6, 2023, with monthly lease payment of \$3,327 (€2,265). Management has assessed that the lease is a finance lease. The lease is guaranteed by BPI.

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2017
(Expressed in Canadian Dollars)

14. LICENSING AGREEMENTS

Agreement with Wanbang Biopharmaceuticals (“Wanbang”)

On January 23, 2014, the Company entered into a licensing and co-development agreement with Wanbang, pursuant to which the Company grants an exclusive, non-sublicensable, non-transferrable license of its IP rights to use the licensed information to conduct clinical research, development, registration, promotion, manufacturing and distribution and sales of anti-diabetic SGLT2 inhibitor in the People’s Republic of China excluding Hongkong and Macau. In consideration for the license grant, Wanbang agrees to make upfront, milestone and royalty payments as below:

- i. US\$200,000 upon the signing of this agreement (paid in F2014 and recorded as revenue);
- ii. US\$300,000 upon successful completion of the first line test (paid in F2016 and recorded as revenue);
- iii. US\$500,000 upon successful filing of IND application under CFDA;
- iv. US\$500,000 upon receipt of CTA by CFDA for a Phase I study in the territory;
- v. US\$1,500,000 upon receipt of CTA by CFDA for a Phase III study;
- vi. US\$2,500,000 upon successful completion of a first Phase III study;
- vii. US\$4,000,000 upon NDA approval by CFDA in the territory; and
- viii. Running royalties of 5% on product net sales during the royalty period.

Agreement with Obagi Medical Products (“Obagi”)

On January 14, 2014, the Company entered into a licensing agreement, pursuant to which the Company grants an exclusive, worldwide license to Obagi for the commercialization of skin lightening compound TFC-849 in the skin condition field. In exchange for the license grant, Obagi agrees to make following two royalty pre-payments and royalties of 4.5% based on net sales of products:

- i) Upfront royalty pre-payment: US\$50,000 within 10 days of execution of this agreement; which has been paid (actual receipt of \$54,500 was recorded as deferred revenue as of July 31, 2017 and October 31, 2016).
- ii) Success criteria milestones: US\$50,000 upon the earlier of 1) first achievement by a Development Product of Obagi’s success criteria which includes i) suitable incorporation of Compound into a reasonably cosmetically elegant formulation upon application of reasonable efforts by Obagi or its contractors; ii) successful completion of compatibility and/or stability testing of such licensed product; and iii) successful efficacy testing of such Licensed Product, and 2) the first commercial sale of license product. (Not yet received as of July 31, 2017)

These pre-paid royalty amount will be deducted from the initial running royalty payments based on net sales of development product.

15. EMPLOYEE BENEFITS

As of July 31, 2017 and October 31, 2016, the employee benefit amount represent the retirement allowance payable accrued by TFC. The obligation of TFC is limited to legal obligations applicable in France. For each employee, a calculation is made based on future benefits they have earned during their service in the current and prior years. The benefit is discounted to determine its present value. The calculation is made annually using the projected benefit method using following assumptions:

- Discount rate: 1.07%
- Increase in salaries: 1.50%
- Turnover: 2.70%

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
 July 31, 2017
 (Expressed in Canadian Dollars)

16. SHARE CAPITAL

Share capital

- a) Authorized: Unlimited common shares without par value.
- b) Issued: As of July 31, 2017, 165,797,548 (October 31, 2016: 165,097,548) common shares were issued and outstanding.

During the nine months ended July 31, 2017, 700,000 shares were issued for the exercise of options.

On May 11, 2016, the Company completed a private placement for total gross proceeds of \$829,500. The private placement consists of 4,147,500 units at \$0.2 per unit. Each unit consists of one common share of the Company and one-half of one transferable share purchase warrant. Each warrant is exercisable into an additional common share of the Company for a period of two years at a price of \$0.3 per warrant. As finders' fee, the Company paid \$24,000 in cash.

During the year ended October 31, 2016, 3,584,000 shares were issued for the exercise of options, 380,000 shares were issued for the exercise of warrants, and 5,583,333 shares were issued for conversion of loan balances.

Warrants

	Number of Warrants	Weighted average exercise price	Weighted average remaining contractual life (year)
Balance at October 31, 2015	9,245,970	\$ 0.20	1.35
Warrants granted exercisable on or before May 11, 2018	2,073,750	0.30	1.53
Warrants exercised	(380,000)	0.20	-
Balance at October 31, 2016	10,939,720	\$ 0.22	0.57
Warrants expired	(15,200)	0.20	-
Balance at July 31, 2017	10,924,520	\$ 0.22	0.42

At July 31, 2017, the warrants outstanding and exercisable were as follows:

Expiry Date	Exercise Price	Number of Warrants as at July 31, 2017
November 30, 2017	\$ 0.20	8,850,700 *
May 11, 2018	\$ 0.30	2,073,750
		10,924,450

* The expiry date is extended from March 7, 2017 to November 30, 2017

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2017
(Expressed in Canadian Dollars)

16. SHARE CAPITAL (continued)

Stock options

At July 31, 2017, the stock options outstanding and exercisable were as follows:

Expiry Date	Exercise Price	Number of Options as at October 31, 2016	Granted During the Period	Exercised During the Period	Expired/Cancelled During the Period	Number of Options as at July 31, 2017	Number of Options Exercisable as at July 31, 2017
March 10, 2017	\$0.20	500,000	-	-	(500,000)	-	-
April 15, 2017	\$0.16	400,000	-	-	(400,000)	-	-
June 26, 2017	\$0.16	600,000	-	-	(600,000)	-	600,000
August 31, 2017	\$0.15	1,000,000	-	(100,000)	-	900,000	900,000 *
October 13, 2017	\$0.18	200,000	-	-	(200,000)	-	-
November 25, 2017	\$0.19	900,000	-	-	-	900,000	900,000
December 17, 2017	\$0.10	50,000	-	-	-	50,000	50,000
January 31, 2018	\$0.19	300,000	-	-	-	300,000	300,000 **
February 15, 2018	\$0.175	-	600,000	(600,000)	-	-	-
April 11, 2018	\$0.195	50,000	-	-	-	50,000	50,000
June 25, 2018	\$0.15	700,000	-	-	-	700,000	700,000
August 25, 2018	\$0.16	100,000	-	-	-	100,000	100,000
September 21, 2018	\$0.20	500,000	-	-	-	500,000	500,000
November 22, 2018	\$0.15	1,100,000	-	-	-	1,100,000	1,100,000
February 19, 2019	\$0.15	300,000	-	-	-	300,000	300,000
April 2, 2019	\$0.10	800,000	-	-	-	800,000	800,000
April 25, 2019	\$0.11	750,000	-	-	-	750,000	750,000
February 25, 2020	\$0.15	300,000	-	-	-	300,000	300,000
June 21, 2021	\$0.20	400,000	-	-	-	400,000	400,000
November 3, 2021	\$0.15	400,000	-	-	-	400,000	400,000
January 20, 2022	\$0.18	-	100,000	-	-	100,000	100,000
June 26, 2025	\$0.16	3,300,000	-	-	-	3,300,000	3,300,000
September 21, 2026	\$0.20	900,000	-	-	-	900,000	900,000
		13,550,000	700,000	(700,000)	(1,700,000)	11,850,000	12,450,000

* The expire date is amended from February 25, 2020 to August 31, 2017

** The expire date is amended from November 25, 2017 to January 31, 2018

The weighted average contractual life remaining of all stock options as at July 31, 2017 is 3.82 years (October 31, 2016: 4.2 years). During the nine months period ended July 31, 2017, 700,000 stock options were granted with a weighted average exercise price of \$0.18. 700,000 stock options were exercised and 1,700,000 stock options were cancelled during the nine months period ended July 31, 2017.

The fair value of the options granted was estimated using the Black-Scholes option pricing model with the following estimated assumptions:

	2017
Risk-free interest rate	0.55%-0.73%
Dividend yield	0%
Volatility	70%-72%
Expected life	0.5-2.5 years

The Company's stock option plan is administered by the board of directors in accordance with Exchange requirements summarized below.

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2017
(Expressed in Canadian Dollars)

16. SHARE CAPITAL (cont'd)

Stock options (continued)

- (i) maximum available for grant is up to 10% of the Company's issued shares outstanding at any one time;
- (ii) grant price and exercise price may not be less than the discounted market price of the shares at the time of grant, as permitted by Exchange policy;
- (iii) non-transferable, vesting schedule subject to Board discretion when granted and exercisable up to 5 years from grant date;
- (iv) eligibility includes employees, directors, officers and consultants of the Company subject to a 5% limitation on options granted annually to any one individual director or officer and 2% to any one consultant;
- (v) exercisable up to 90 days following cessation of the optionee's position with the Company. If the cessation of office, directorship or consulting arrangement was due to death, the option may be exercised within a maximum period of one year after death, subject to expiry date of such option.

Option pricing models require the input of highly subjective assumptions including the expected price volatility. Changes in the subjective input assumptions can materially affect the fair value estimate, and therefore the existing models do not necessarily provide a reliable single measure of the fair value of the Company's stock options.

Escrow Shares

As at July 31, 2017, there were nil common shares (October 31, 2016 – 975,000) held in escrow subject to Section 11(5) of Exchange Policy 2.4.

17. RELATED PARTY TRANSACTIONS

Related parties and related party transactions impacting the accompanying financial statements are summarized below and include transactions with the following individuals and entities:

Key management personnel:

Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of executive and non-executive members of the Company's Board of Directors and corporate officers.

During nine months ended July 31, 2017 and 2016, the Company incurred the following expenses to officers or directors of the Company or companies with common directors:

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2017
(Expressed in Canadian Dollars)

17. RELATED PARTY TRANSACTIONS (cont'd)

Related party transactions	Nine months ended July 31,	
	2017	2016
	\$	\$
Management fees (Howard Verrico, for acting as CEO)	108,000	108,000
Accounting fees (Christopher Hopton, for acting as CFO)	99,000	99,000
Share-based payments	-	96,219
Director fee	-	1,500
Total	207,000	304,719

As of July 31, 2017 and October 31, 2016, \$nil balance is owing to related parties.

These transactions are in the normal course of operations and have been valued in these consolidated financial statements at the exchange amount which is the amount of consideration established and agreed to by the related parties.

18. GEOGRAPHIC SEGMENT AND ECONOMIC DEPENDENCE

The Company and its subsidiary TFC are considered to be operating in one segment based on its business nature and strategic decision making method.

The Company is located and operated in Canada and France. The Company's suppliers are well diversified and no one supplier accounted for more than 10% of total sales, due to its business nature.

The Company's net income (loss) by geographic locations for the period ended July 31, 2017 and 2016 are as follows:

	Nine months ended	
	July 31, 2017	July 31, 2016
Net loss		
Canada	\$ 311,836	\$ 975,086
France	1,579,072	1,106,205
Total	\$ 1,890,908	\$ 2,081,291

The Company's total assets by geographic locations are as follows:

	July 31, 2017	October 31, 2016
Total assets		
Canada	\$ 81,824	\$ 727,954
France	2,660,503	2,397,093
Total	\$ 2,742,327	\$ 3,125,047

SIRONA BIOCHEM CORP.
NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2017
(Expressed in Canadian Dollars)

19. COMMITMENTS

On June 1, 2013, the Company commenced a lease assignment agreement with Impex Management Ltd., a non-related party, whereby the Company entered five-year lease for a monthly fee of \$4,913, which expires on May 31, 2018.

2017	\$	58,958
2018		34,392
Total	\$	<u>93,350</u>

On April 1, 2015, the Company entered into an indefinite management service agreement with Christopher Hopton, whereby Christopher Hopton will receive \$11,000 (plus GST) per month until the agreement is terminated by either party.

On April 1, 2015, the Company entered into an indefinite management service agreement with Howard Verrico, whereby Howard Verrico will receive \$12,000 (plus GST) per month until the agreement is terminated by either party.

20. SUBSEQUENT EVENTS

None.